Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1 : affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. / Thomsen, Anne Engelbrecht; Friedrichsen, Gerda Marie; Sørensen, Arne Hagsten; Andersen, Rikke; Nielsen, Carsten Uhd; Brodin, Birger; Begtrup, Mikael; Frokjaer, Sven; Steffansen, Bente.

In: Journal of Controlled Release, Vol. 86, No. 2-3, 2003, p. 279-92.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thomsen, AE, Friedrichsen, GM, Sørensen, AH, Andersen, R, Nielsen, CU, Brodin, B, Begtrup, M, Frokjaer, S & Steffansen, B 2003, 'Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism', Journal of Controlled Release, vol. 86, no. 2-3, pp. 279-92.

APA

Thomsen, A. E., Friedrichsen, G. M., Sørensen, A. H., Andersen, R., Nielsen, C. U., Brodin, B., Begtrup, M., Frokjaer, S., & Steffansen, B. (2003). Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. Journal of Controlled Release, 86(2-3), 279-92.

Vancouver

Thomsen AE, Friedrichsen GM, Sørensen AH, Andersen R, Nielsen CU, Brodin B et al. Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. Journal of Controlled Release. 2003;86(2-3):279-92.

Author

Thomsen, Anne Engelbrecht ; Friedrichsen, Gerda Marie ; Sørensen, Arne Hagsten ; Andersen, Rikke ; Nielsen, Carsten Uhd ; Brodin, Birger ; Begtrup, Mikael ; Frokjaer, Sven ; Steffansen, Bente. / Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1 : affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism. In: Journal of Controlled Release. 2003 ; Vol. 86, No. 2-3. pp. 279-92.

Bibtex

@article{9a975b8340bd408fac5cc87d2dac0236,
title = "Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism",
abstract = "A general drug delivery approach for increasing oral bioavailability of purine and pyrimidine analogues such as acyclovir may be to link these compounds reversibly to stabilized dipeptide pro-moieties with affinity for the human intestinal di/tri-peptide transporter, hPepT1. In the present study, novel L-Glu-Sar and D-Glu-Ala ester prodrugs of acyclovir and 1-(2-hydroxyethyl)-linked thymine were synthesized and their affinities for hPepT1 in Caco-2 cells were determined. Furthermore, the degradation of the prodrugs was investigated in various aqueous and biological media and compared to the corresponding hydrolysis of the prodrug valaciclovir. Affinity studies showed that the L-Glu-Sar prodrugs had high affinity for hPepT1 (K(i) approximately 0.2-0.3 mM), whereas the D-Glu-Ala prodrugs had poor affinity (K(i) approximately 50 mM). The pH-rate profiles of the prodrugs D-Glu[1-(2-hydroxyethyl)thymine]-Ala and L-Glu[acyclovir]-Sar showed specific base catalyzed degradation at pH above 4.5 and 5.5, respectively. This implicates that the degradation rates at pH approximately 7.4 (t(1/2) approximately 3.5 and 5.5 h) are approximately 25 times faster than at upper small intestinal pH approximately 6.0. In 10% porcine intestinal homogenate and 80% human plasma the half-lives of the L-Glu-Sar prodrugs were approximately between 45 and 90 min indicating a limited enzyme catalyzed degradation. In contrast, valaciclovir underwent extensive enzyme catalyzed hydrolysis in 10% porcine intestinal homogenate (t(1/2) approximately 1 min). In conclusion, L-Glu-Sar may potentially function as pro-moiety for purine and pyrimidine analogues, where release of parent compound primarily is controlled by a specific base catalyzed hydrolysis. Acyclovir is quantitatively released at the relevant pH 7.4, whereas the 1-(2-hydroxyethyl)-linked thymine is released instead of the parent compound thymine.",
keywords = "Caco-2 Cells, Carrier Proteins, Humans, Prodrugs, Purines, Pyrimidines, Solutions, Symporters",
author = "Thomsen, {Anne Engelbrecht} and Friedrichsen, {Gerda Marie} and S{\o}rensen, {Arne Hagsten} and Rikke Andersen and Nielsen, {Carsten Uhd} and Birger Brodin and Mikael Begtrup and Sven Frokjaer and Bente Steffansen",
year = "2003",
language = "English",
volume = "86",
pages = "279--92",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2-3",

}

RIS

TY - JOUR

T1 - Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1

T2 - affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism

AU - Thomsen, Anne Engelbrecht

AU - Friedrichsen, Gerda Marie

AU - Sørensen, Arne Hagsten

AU - Andersen, Rikke

AU - Nielsen, Carsten Uhd

AU - Brodin, Birger

AU - Begtrup, Mikael

AU - Frokjaer, Sven

AU - Steffansen, Bente

PY - 2003

Y1 - 2003

N2 - A general drug delivery approach for increasing oral bioavailability of purine and pyrimidine analogues such as acyclovir may be to link these compounds reversibly to stabilized dipeptide pro-moieties with affinity for the human intestinal di/tri-peptide transporter, hPepT1. In the present study, novel L-Glu-Sar and D-Glu-Ala ester prodrugs of acyclovir and 1-(2-hydroxyethyl)-linked thymine were synthesized and their affinities for hPepT1 in Caco-2 cells were determined. Furthermore, the degradation of the prodrugs was investigated in various aqueous and biological media and compared to the corresponding hydrolysis of the prodrug valaciclovir. Affinity studies showed that the L-Glu-Sar prodrugs had high affinity for hPepT1 (K(i) approximately 0.2-0.3 mM), whereas the D-Glu-Ala prodrugs had poor affinity (K(i) approximately 50 mM). The pH-rate profiles of the prodrugs D-Glu[1-(2-hydroxyethyl)thymine]-Ala and L-Glu[acyclovir]-Sar showed specific base catalyzed degradation at pH above 4.5 and 5.5, respectively. This implicates that the degradation rates at pH approximately 7.4 (t(1/2) approximately 3.5 and 5.5 h) are approximately 25 times faster than at upper small intestinal pH approximately 6.0. In 10% porcine intestinal homogenate and 80% human plasma the half-lives of the L-Glu-Sar prodrugs were approximately between 45 and 90 min indicating a limited enzyme catalyzed degradation. In contrast, valaciclovir underwent extensive enzyme catalyzed hydrolysis in 10% porcine intestinal homogenate (t(1/2) approximately 1 min). In conclusion, L-Glu-Sar may potentially function as pro-moiety for purine and pyrimidine analogues, where release of parent compound primarily is controlled by a specific base catalyzed hydrolysis. Acyclovir is quantitatively released at the relevant pH 7.4, whereas the 1-(2-hydroxyethyl)-linked thymine is released instead of the parent compound thymine.

AB - A general drug delivery approach for increasing oral bioavailability of purine and pyrimidine analogues such as acyclovir may be to link these compounds reversibly to stabilized dipeptide pro-moieties with affinity for the human intestinal di/tri-peptide transporter, hPepT1. In the present study, novel L-Glu-Sar and D-Glu-Ala ester prodrugs of acyclovir and 1-(2-hydroxyethyl)-linked thymine were synthesized and their affinities for hPepT1 in Caco-2 cells were determined. Furthermore, the degradation of the prodrugs was investigated in various aqueous and biological media and compared to the corresponding hydrolysis of the prodrug valaciclovir. Affinity studies showed that the L-Glu-Sar prodrugs had high affinity for hPepT1 (K(i) approximately 0.2-0.3 mM), whereas the D-Glu-Ala prodrugs had poor affinity (K(i) approximately 50 mM). The pH-rate profiles of the prodrugs D-Glu[1-(2-hydroxyethyl)thymine]-Ala and L-Glu[acyclovir]-Sar showed specific base catalyzed degradation at pH above 4.5 and 5.5, respectively. This implicates that the degradation rates at pH approximately 7.4 (t(1/2) approximately 3.5 and 5.5 h) are approximately 25 times faster than at upper small intestinal pH approximately 6.0. In 10% porcine intestinal homogenate and 80% human plasma the half-lives of the L-Glu-Sar prodrugs were approximately between 45 and 90 min indicating a limited enzyme catalyzed degradation. In contrast, valaciclovir underwent extensive enzyme catalyzed hydrolysis in 10% porcine intestinal homogenate (t(1/2) approximately 1 min). In conclusion, L-Glu-Sar may potentially function as pro-moiety for purine and pyrimidine analogues, where release of parent compound primarily is controlled by a specific base catalyzed hydrolysis. Acyclovir is quantitatively released at the relevant pH 7.4, whereas the 1-(2-hydroxyethyl)-linked thymine is released instead of the parent compound thymine.

KW - Caco-2 Cells

KW - Carrier Proteins

KW - Humans

KW - Prodrugs

KW - Purines

KW - Pyrimidines

KW - Solutions

KW - Symporters

M3 - Journal article

C2 - 12526824

VL - 86

SP - 279

EP - 292

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2-3

ER -

ID: 37899617